Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
Cisplatin superior to cetuximab for HPV oropharyngeal cancer

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 489

Prof Hisham Mehanna - University of Birmingham , Birmingham, UK

Prof Hisham Mehanna speaks with ecancer at ESMO 2018 in Munich about results from a trial comparing cetuximab and cisplatin for patients with HPV-related oropharyngeal cancer receiving radical radiotherapy.

While the suitability of cetuximab had been suggested in other trials, Prof Mehanna reports that it is not only non-superior to cisplatin for disease control and toxicity, but that patients receiving it actually fare worse, and it should no longer be offered.

For more on these results, watch their presentation at a press session.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation